RATIO-LISINOPRIL Z TABLET

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

LISINOPRIL

Disponible des:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

Codi ATC:

C09AA03

Designació comuna internacional (DCI):

LISINOPRIL

Dosis:

10MG

formulario farmacéutico:

TABLET

Composición:

LISINOPRIL 10MG

Vía de administración:

ORAL

Unidades en paquete:

100/500

tipo de receta:

Prescription

Área terapéutica:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Resumen del producto:

Active ingredient group (AIG) number: 0121550001; AHFS:

Estat d'Autorització:

CANCELLED POST MARKET

Data d'autorització:

2014-09-19

Fitxa tècnica

_ _
_ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _
_Page 1 of 39 _
PRODUCT MONOGRAPH
RATIO-LISINOPRIL Z
Lisinopril
Tablets 5 mg, 10 mg and 20 mg
USP
Angiotensin Converting Enzyme Inhibitor
ratiopharm inc.
Canada J7J 1P3
DATE OF PREPARATION: SEPTEMBER 20, 2007
CONTROL NUMBER: 110419
_ _
_ratio-LISINOPRIL Z 5 mg, 10 mg and 20 mg Tablets _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
……………………………………………………..4
ADVERSE
REACTIONS.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND
ADMINISTRATION.............................................................................
16
SYMPTOMS AND TREATMENT OF OVERDOSAGE
............................................... 19
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 19
STORAGE AND
STABILITY.........................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 22
PART II: SCIENTIFIC INFORMATION
..............................................................................
23
PHARMACEUTICAL
INFORMATION.........................................................................
23
CLINICAL
TRIALS.........................................................................................................
24
DETAILED
PHARMACOLOGY...............................................................